Whole-exome profiles of inflammatory breast cancer and pathological response to neoadjuvant chemotherapy.

ABSTRACT:

Background

Neoadjuvant chemotherapy (NACT) became a standard treatment strategy for patients with inflammatory breast cancer (IBC) because of high disease aggressiveness. However, given the heterogeneity of IBC, no molecular feature reliably predicts the response to chemotherapy. Whole-exome sequencing (WES) of clinical tumor samples provides an opportunity to identify genomic alterations associated with chemosensitivity.

Methods

We retrospectively applied WES to 44 untreated IBC primary tumor samples and matched normal DNA. The pathological response to NACT, assessed on operative specimen, distinguished the patients with versus without pathological complete response (pCR versus no-pCR respectively). We compared the mutational profiles, spectra and signatures, pathway mutati

SUBMITTER: Bertucci F 

PROVIDER: S-EPMC11514970 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature